Vaxcyte (PCVX) Total Liabilities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Total Liabilities data on file, last reported at $352.3 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $352.3 million, up 97.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $352.3 million (up 97.83% YoY), and the FY2025 annual result was $317.2 million, up 54.36% from the prior year.
• Total Liabilities grew to $352.3 million in Q1 2026 per PCVX's latest filing, from $317.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $352.3 million in Q1 2026 and troughed at $43.2 million in Q1 2022.
• A 5-year average of $147.3 million and a median of $107.3 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities declined 22.09% in 2022, then surged 218.56% in 2023.
• A 5-year view of Total Liabilities shows it stood at $52.6 million in 2022, then surged by 218.56% to $167.4 million in 2023, then climbed by 22.72% to $205.5 million in 2024, then soared by 54.36% to $317.2 million in 2025, then climbed by 11.06% to $352.3 million in 2026.
• Business Quant data shows PCVX's Total Liabilities at $352.3 million in Q1 2026, $317.2 million in Q4 2025, and $278.7 million in Q3 2025.